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Patient-derived cell lines and animal models have proven invaluable for the
understanding of human intestinal diseases and for drug development although both
inherently comprise disadvantages and caveats. Many genetically determined intestinal
diseases occur in specific tissue microenvironments that are not adequately modeled by
monolayer cell culture. Likewise, animal models incompletely recapitulate the complex
pathologies of intestinal diseases of humans and fall short in predicting the effects of
candidate drugs. Patient-derived stem cell organoids are new and effective models
for the development of novel targeted therapies. With the use of intestinal organoids
from patients with inherited diseases, the potency and toxicity of drug candidates
can be evaluated better. Moreover, owing to the novel clustered regularly interspaced
short palindromic repeats/CRISPR-associated protein-9 genome-editing technologies,
researchers can use organoids to precisely modulate human genetic status and identify
pathogenesis-related genes of intestinal diseases. Therefore, here we discuss how
patient-derived organoids should be grown and how advanced genome-editing tools
may be applied to research on modeling of cancer and infectious diseases. We also
highlight practical applications of organoids ranging from basic studies to drug screening
and precision medicine.
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INTRODUCTION
The intestinal epithelium is a tissue with an extreme self-renewal capacity fueled by Lgr5+ intestinal
stem cells (ISCs; Sato et al., 2009; Rookmaaker et al., 2015; Sato and Clevers, 2015; Vetizou et al.,
2015). These cells give rise to daughter or progenitor cells that can differentiate into mature
epithelial cells required for normal gut function (Sato et al., 2009; Petersen et al., 2014; Sterneckert
et al., 2014). Homeostasis of the normal intestinal epithelium is ensured by continuous and rapid
turnover of differentiated cells compensated by replication of ISCs which is commonly marked by
Lgr5, a seven-transmembrane receptor as a marker of Wnt-regulated adult stem cell populations
in the intestine, stomach, pancreas, and prostate (Sato et al., 2009; Snippert et al., 2010; Bas
and Augenlicht, 2014; Peterson and Artis, 2014; Vereecke et al., 2014; Kabouridis et al., 2015).
Nonetheless, in various pathological conditions, this renewal process can become substantially
disordered, resulting in a loss of epithelial integrity, in local inflammation, or even carcinogenesis
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(Peterson and Artis, 2014; McFarlane et al., 2015; van de Wetering
et al., 2015; Amieva and Peek, 2016). Diseases of the intestinal
epithelium include chronic disorders such as inflammatory
bowel disease (IBD) and gastrointestinal (GI) cancers (Jostins
et al., 2012; Mokry et al., 2014; Neurath, 2014; Okamoto and
Watanabe, 2015; Stedman et al., 2015). Unfortunately, due to
unavailability of effective drugs for treatment of these diseases,
the mortality rates remain unacceptably high (Okamoto and
Watanabe, 2015). The exceptional costs and the relative paucity
of new drug approvals are in large part due to the failure to
establish biomimetic platforms in initial in vitro screens in order
to predict which drugs will perform as intended in vivo (Mokry
et al., 2014; van de Wetering et al., 2015). Two-dimensional
(2D) monocultures of cell lines lose cell-matrix interactions that
are necessary to maintain in situ phenotypes and thus fail to
sustain cellular functions that exist in tissues (Jabaji et al., 2013;
Gould et al., 2015). Although animal models recapitulate in vivo
physiology closely, the most obvious problem is the fundamental
difference between animal and human biology (Huch et al.,
2013a,b; Karthaus et al., 2014; Nanduri et al., 2014; Gould et al.,
2015).
The widespread implementation of organoid technologies
provides a more physiologically relevant platform for high-
throughput screening during drug discovery (Eglen and Randle,
2015; Walsh et al., 2016). An organoid means ex vivo three-
dimensional (3D) tissue originating from organ stem cells,
embryonic stem cells (ESCs), or induced pluripotent stem cells
(iPSCs), with structure and function similar to those of the
original organ to some degree (McCracken et al., 2011; Fuller
et al., 2012; Lancaster and Knoblich, 2014; Ordonez-Moran
et al., 2015; Tamminen et al., 2015; Wieck et al., 2015). So far,
various organoid systems have been successfully established from
a specific organ and could be expanded infinitely (Sato et al.,
2011; Hisha et al., 2013; Mahe et al., 2013; Takebe et al., 2013;
Gehart and Clevers, 2015; Rookmaaker et al., 2015; Xinaris et al.,
2015; Yin et al., 2016). For intestinal epithelial organoids, also
termed the mini-gut, tissue stem cells or ESCs/iPSCs can form
a crypt-villus structure that mimics in vivo gastric, intestinal, or
colonic epithelial structures (Stange et al., 2013; DeWard et al.,
2014; Watson et al., 2014; Rookmaaker et al., 2015; Salahudeen
and Kuo, 2015).
In vitro organoids have various advantages over traditional
animal models and cell culture systems in human physiological
research and disease modeling because (i) an organoid in
3D culture can develop and expand in all directions, thus
simulating organ development and morphological features
in vivo (Mahe et al., 2013; Lancaster and Knoblich, 2014);
(ii) an organoid derived from a human organ can maintain
its in vivo characteristics stably and purely after passaging for
many generations without significant genetic or physiological
changes (DiMarco et al., 2014; Grabinger et al., 2014); (iii) GI
organoid models can be easily established by isolating epithelial
crypts from the mouse GI tract or a human GI biopsy, and
crypts can grow into crypt-villus structures in less than 7
days; (iv) the clustered regularly interspaced short palindromic
repeats/CRISPR-associated protein-9 (CRISPR/Cas9) system has
made it feasible to correct or change the human genome
in vitro, and the off-target effects manifest themselves less during
correction of organoid genes (Gao et al., 2014; Gregorieff et al.,
2015). For the reasons given above, a 3D organoid has a great
potential for drug screening and personalized medicine (Miyoshi
et al., 2012; Li et al., 2014; Drost et al., 2015; Janeckova et al.,
2015; Kitamura et al., 2015; Oshima et al., 2015; Riemer et al.,
2015; van de Wetering et al., 2015). Moreover, organoid buds
originating from iPSCs and successful use of CRISPR/Cas9-
mediated correction in patients with cystic fibrosis (CF) show
great promise for organ transplantation and gene therapy (Eglen
and Randle, 2015; van de Wetering et al., 2015; Walsh et al., 2016).
In this review, we discuss the recent developments in gut
organoids from primary tissues and pluripotent stem cells.
We critically appraise the advantages of organoids as model
systems for research into human intestinal diseases related to
immunological disorders (Mahe et al., 2013; Peterson and Artis,
2014; Nguyen-Ngoc et al., 2015; Rogoz et al., 2015). We also
highlight the potential applications of organoids to clinical
drug screening and stem cell transplantation as well as their
significance for drug discovery and precision medicine (Mahe
et al., 2015; Okamoto and Watanabe, 2015; Schumacher et al.,
2015).
TECHNOLOGIES OF CURRENT
INTESTINAL EPITHELIAL ORGANOID
The most widely used intestinal cellular model is the Caco-2 cell
line in 2D culture. An improvement of this model is achieved
via cell growth on a microporous membrane allowing for free
access of nutrients to either the basolateral or the apical side of the
cellular monolayer (Eglen and Randle, 2015; Gould et al., 2015).
Another key improved method is co-culture of different cell types
in two filters, where they share soluble factors in the medium
without a direct physical contact. Nevertheless, intestinal cells
growing as a 2D monolayer lack organ-specific microarchitecture
and the physiological extracellular matrix microenvironment.
Indeed, in drug development, only 5% of the compounds that are
found effective in such 2D models reach clinical trials (Eglen and
Randle, 2015).
It is likely that 3D culture may provide more reliable cellular
models and help to reduce the number of animals used for
drug toxicity and efficacy tests (Dekkers et al., 2013; Eglen
and Randle, 2015; van de Wetering et al., 2015). Currently,
there are several 3D culture methods, including the scaffold-
based models (hydrogels or solid biomaterials) and scaffold-
free platforms for spheroid growth. In 2009, the first culture
system for an intestinal epithelial organoid (mini-gut) was
established by means of mouse Lgr5+ ISCs (Sato et al., 2009).
A single ISC may form 3D crypt structures in a serum-free
and mesenchyme-free growth environment containing Matrigel,
epidermal growth factor (EGF), Noggin, and R-spondin 1 (Barker
et al., 2010; Snippert et al., 2010; Yui et al., 2012; Koo and Clevers,
2014). These mini-guts comprise distinct cell types including
Lgr5+ ISCs, enterocytes, enteroendocrine cells, goblet cells, and
Paneth cells normally present in the gut (Yin et al., 2014).
Later, human mini-guts are seeded in a 3D laminin-rich matrix
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(Mohamed et al., 2014; Jung et al., 2015). Mini-organoids that
effectively mimic GI epithelial structure and functional features
can be readily generated from crypt stem cells by chelation
with 2 mM ethylenediaminetetraacetic acid (EDTA) (Sato et al.,
2011). Intestinal crypts are harvested from the human GI tract,
then an organoid is grown in the presence of R-spondin, EGF,
Wnt3a, Noggin, and other essential growth factors (Peignon
et al., 2011; Sato et al., 2011; Demitrack et al., 2015). The crypts
form round clear spheres soon after plating, then start to bud
continuously 3–5 days later on (Sato et al., 2011). The cell types
such as goblet cells, endocrine cells, and enteroendocrine cells
appear and surround the central lumen in a single-layer manner,
while ISCs and Paneth cells form the bud part of the mini-gut
(Jung et al., 2011; Grun et al., 2015; Horvay et al., 2015). In
contrast to the structure in the intestine, the ISCs and Paneth
cells that are present in the crypt domain and other cells form
a villus toward the intestinal lumen (Jung et al., 2011). Usually,
organoids are passaged for 7–10 days post-cultivation (Wang
et al., 2013). Intestinal organoids can be stably passaged and
retain their morphological and genetic characteristics for months
and years. Similar protocols and cultivation protocols can be
applied to gastric and colon organoids, except that they need
additional growth factors like gastrin and FGF10 (Barker et al.,
2010; Schumacher et al., 2015; Wroblewski et al., 2015).
Although a mini-gut recapitulates many characteristics of
the intestine in vivo, the limitations still exist. (i) Mini-
guts do not undergo physical stretching that is caused by
peristaltic contractions in vivo (Barker et al., 2010); (ii)
bone morphogenetic protein (BMP) inhibitor Noggin diffuses
throughout the organoid from the culture medium; this situation
leads to the lack of a BMP signaling gradient in intestinal
organoids (Shroyer and Wong, 2007); (iii) in human colon and
intestinal organoid culture, Wnt and other factors (such as p38
inhibitor, transforming growth factor beta (TGF-β) inhibitor, and
nicotinamide) prevent stem cell differentiation and reduce cell
diversity (Miyoshi et al., 2012; de Lau et al., 2014; Germann
et al., 2014; Krausova and Korinek, 2014); (iv) intestinal epithelial
organoids consist mainly of epithelial cells without interaction
with mesenchymal cells (Wilson et al., 2015). This problem can
be overcome with embryonic or iPSCs that can form organoids
including subepithelial myofibroblasts, immune cells, and enteric
nerves (Spence et al., 2011; Takebe et al., 2013).
In addition, modeling of intestinal diseases can be improved
by introducing additional cell types from lineages other than
the epithelium (Lindemans et al., 2015; Vetizou et al., 2015;
Pastula et al., 2016). For instance, co-culturing of an intestinal
organoid with Paneth cells significantly increases the plating
efficiency (Shamir and Ewald, 2014). A microvascular niche
has also been successfully generated through co-culturing of
tumor cells with stromal cells and endothelial cells (Shamir and
Ewald, 2014). To study the complex interaction of intestinal
epithelial cells (IECs) and immune cells or microbiota, a model
has been optimized to have features similar to those of the
in vivo system (Table 1). An organoid is cultured together
with cytokines produced by immune cells or directly with
CD8+ T cells (Lindemans et al., 2015; Vetizou et al., 2015).
This system allows researchers to examine the proliferation,
activation, and movement of an epithelial lymphoid in vitro
(Vetizou et al., 2015). Moreover, enteric pathogens can colonize
the GI organoid through microinjection (Bartfeld and Clevers,
2015). The infected models can be genetically manipulated
via short hairpin RNA or CRISPR interference single guide
RNA afterward, enabling investigators to thoroughly analyze the
effects on epithelial homeostasis, regeneration, inflammation,
and gastric carcinogenesis (Figure 1; Andersson-Rolf et al., 2014;
Van Lidth de Jeude et al., 2015).
The proof-of-concept use of genome editing in an intestinal
organoid was recently demonstrated (Cao et al., 2015; Guye et al.,
2016). The mutation (deletion of phenylalanine at position 508)
of the CF transmembrane conductance regulator (CFTR) is the
primary cause of CF (Liu et al., 2012; Dekkers et al., 2013, 2015;
Schneeberger et al., 2015; Than et al., 2016). Intestinal organoids
from two CF patients were genome-edited to correct the
mutation through CRISPR/Cas9-mediated homology-directed
repair (Dekkers et al., 2013; Wiegerinck et al., 2014). Matano
et al. (2015) introduced multiple mutations of niche signaling
pathways into intestinal epithelial organoids by CRISPR gene
editing. Thus, their roles in tumorigenesis and metastases could
be elucidated (Matano et al., 2015; Hong et al., 2016; Sakaguchi
et al., 2016). Evolutional genome-editing approaches create
next-generation organoid systems, advancing the research on
intestinal homeostasis, pathogenesis, organoid-based therapies,
intestinal neoplasms, and organoid-based drug screening (Fujii
et al., 2015; Matano et al., 2015).
TABLE 1 | Optimization of organoids for immunological research.
In vitro models Research area Finding References
Co-culture with lymphocytes Cancer immunotherapy Cytotoxic T-lymphocyte-associated protein
4 (CTLA-4) blocker relies on the microbiota
in anticancer immunotherapy
Vetizou et al., 2015
Co-culture with interleukin 22
(IL-22) produced by ILCs
Innate immunity and epithelial
homeostasis
ILCs induce ISC regeneration and intestinal
regeneration though signal transducer and
activator of transcription 3 (STAT3) signaling
Lindemans et al., 2015
Gastroid microinjection Gastroid microbiota GI microbiota and its effects on epithelial
homeostasis, regeneration, inflammation,
and gastric carcinogenesis
Hynds and Giangreco, 2013; Foulke-Abel et al.,
2014; Nigro et al., 2014; Pham et al., 2014;
Zhang et al., 2014; Bartfeld et al., 2015
Stem cell transplantation Chronic inflammatory disease Donor stem cells cure DSS colitis and
remain functional for over half a year in an
animal model
Yui et al., 2012; Fordham et al., 2013
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FIGURE 1 | The epithelial innate immune response and its effect on epithelial homeostasis, regeneration, inflammation, and gastric carcinogenesis
after activation of inflammation by a pathogen. Epithelial cells can express pathogen recognition receptors to pass microbial signals (Nigro et al., 2014; Amieva
and Peek, 2016) and generate various peptides against infection and prevent a strong T-cell-mediated immune response (Farin et al., 2014; Leslie et al., 2015);
IEC-produced cytokines and dendritic cells can promote T-cell maturation and differentiation (Liu Y. et al., 2015); innate lymphoid cells can produce IL-22 and then
regulate ISC survival and proliferation (Bermudez-Brito et al., 2013; Lindemans et al., 2015).
INTESTINAL ORGANOIDS FOR
RESEARCH INTO IMMUNE
HOMEOSTASIS MECHANISMS
The intestinal immune system must ensure homeostasis by
offering adequate protection from pathogens and by remaining
tolerant to harmless commensals (McDonald et al., 2008;
Neurath, 2014; Peterson and Artis, 2014). Imbalances of immune
responses may lead to chronic inflammatory disorders such as
IBD (Neurath, 2014; Gao et al., 2015; Amieva and Peek, 2016).
The molecular mechanisms of intestinal homeostasis are not fully
understood. The model of intestinal organoids co-cultured with
immune cells or microorganisms should facilitate identification
of molecular mechanisms underlying intestinal homeostasis
and interactions of the intestinal epithelial barrier with its
environment (Peterson and Artis, 2014; Takahashi et al., 2014;
Nozaki et al., 2016).The essential players in intestinal homeostasis
are the IECs, derived from Paneth cells, goblet cells, endocrine
cells, and enteroendocrine cells (Fuller et al., 2012; Chang et al.,
2015; Takebe et al., 2015). They play a crucial role in the innate
immune system by directly segregating the internal environment
from bacteria and by integrating microbial signals with an innate
immune response (Bartfeld et al., 2015; Liu J. et al., 2015). The
immune homeostasis effects comprise (i) the epithelial cells that
can express Toll-like receptors and other pathogen recognition
receptors that can pass a microbial signal on to dendritic cells
(Ayabe et al., 2000; Nigro et al., 2014; Amieva and Peek,
2016); (ii) Paneth cells and ISCs can generate various peptides
like α-defensin phospholipase A2 group IIA (PLA2G2A) and
regenerating islet-derived protein 3 gamma (REGIII-γ) against
an infection, and thus prevent a strong T-cell-mediated immune
response (Ayabe et al., 2000; Farin et al., 2014; Leslie et al.,
2015); (iii) interleukin 8 (IL-8) and tumor necrosis factor alpha
(TNF-α) are secreted by IECs when a pathogenic microbe is
present and promote dendritic-cell activation (Jostins et al.,
2012; Kabouridis et al., 2015); (iv) IEC-produced cytokines and
dendritic cells can promote T-cell maturation and differentiation
(Liu Y. et al., 2015); (v) innate lymphoid cells (ILCs) can
produce IL-22 (when IECs suffer from injury) and then regulate
ISC survival and proliferation (Bermudez-Brito et al., 2013;
Lindemans et al., 2015). Intraepithelial lymphocytes (IELs) are
believed to be necessary for the maintenance and regulation
of IECs (Peterson and Artis, 2014). Nonetheless, the molecular
mechanisms involved in the interactions between IELs and IECs
remain unclear. Dysregulation of this system may contribute
to the development of intestinal inflammatory diseases such
as celiac disease, IBD, and intestinal cancer (Neurath, 2014;
Sugimoto et al., 2015).
To effectively study the correlation between immune cells and
IECs, several modified organoid systems have been built that
directly apply immune cells or a cytokine generated by immune
cells to research under pathological or physiological conditions
(Neurath, 2014). For example, Nozaki et al. (2016) showed that
IELs can be maintained with epithelial organoids in an IL-2-
, IL-7-, and IL-15-supplemented medium. Fluorescent imaging
revealed an active, multidirectional movement of IELs along
the surface of IECs and their migration relative to organoid
structures (Nozaki et al., 2016). Using a GI organoid and an IL-22
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co-culture system, Lindemans et al. (2015) found that immune
molecules can directly promote the growth of ISCs to enhance
epithelial regeneration. In the co-culture system, IL-22 secreted
by ILCs can induce intestinal organoid growth after injury
in the intestine. IL-22 targets signal transducer and activator
of transcription 3 (STAT3) signaling and leads to organoid
formation and ISC regeneration in vivo. This mechanism was
also proven to be independent of Paneth cells, which means
that ILCs themselves play an important part in the intestinal
barrier repair after damage. This study provides solid evidence
that the immune system can maintain and promote intestinal
regeneration (Gilbert et al., 2015; Lindemans et al., 2015; Zachos
et al., 2015).
The intestinal organoids could be infected with intracellular
pathogens, and this approach may help to identify the
molecular mechanisms governing microbiota–epithelial
interactions (Foulke-Abel et al., 2014; Pham et al., 2014).
For example, Finkbeiner et al. (2012) reported application
of the intestinal organoid system to a model of rotavirus
infection. In addition, a homologous human rhinovirus is
more infectious than a heterologous one (Saxena et al., 2015).
Recently, Wilson et al. (2015) used an organoid system
to explore the mechanisms behind Salmonella enterica
infection. They showed that organoids form a sealed lumen
that contains high concentrations of α-defensins capable of
restricting the growth of S. enterica for at least 20 h (Wilson
et al., 2015). Similarly, Forbester et al. (2015) showed that
Salmonella Typhimurium microinjected into the lumen of
intestinal organoids can invade the epithelial barrier. On the
other hand, a mutation causing a defect in the Salmonella
pathogenicity island 1 invasion apparatus yields a pathogen less
capable of invading the organoid epithelium (Forbester et al.,
2015).
It was also shown that inside the intestinal organoid, bacteria
in the gland induce a much stronger T-cell response and
inflammation than bacteria in the surface layer (Foulke-Abel
et al., 2014; Bartfeld et al., 2015; Zachos et al., 2015). On the
one hand, the mucus layer may protect epithelial cells from
bacteria (Okamoto and Watanabe, 2015). On the other hand,
the host restricts receptors initiating the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activation in
the deeper glands, which are less in contact with bacteria.
A study by Bartfeld et al. (2015) supports the notion that
the epithelial barrier can separate the bacteria that colonize
mucosal surfaces from iron during the inflammation process;
this mechanism represents ancient innate immune defense
against infection. In the gastric mucosa, transferrin, hemoglobin,
ferritin, and neutrophils secreting lactoferrin can bind free
iron. In addition, inflammation upregulates hepcidin, which
reduces iron uptake in the small intestine (Bartfeld et al.,
2015). Antimicrobial proteins secreted by Paneth cells can also
prevent a strong T-cell response on mucosal surfaces (Keshav,
2006).
Although the microbiota poses a threat to an intestinal
organoid, the host–pathogen interactions also have a beneficial
effect on gut epithelial homeostasis (Foulke-Abel et al., 2014).
Bacterial products may interact with the host and potentially
modulate an innate immune response and epithelial regeneration
(Foulke-Abel et al., 2014). Nigro et al. (2014) found that within an
intestinal organoid, Lgr5+ stem cells express the cytosolic innate
immune sensor Nod2 more than it is expressed in Paneth cells,
and microbiota-derived molecules can trigger Nod2 secretion,
which is beneficial for ISC proliferation.
Besides physiological relevance, the intestinal organoid
microbiota model has several other advantages. CRISPR/Cas9-
mediated genome editing in intestinal organoids enables the
studies on gene function under intestinal homeostatic and
pathophysiological conditions (Schwank et al., 2013; Matano
et al., 2015). Furthermore, this system may serve as a promising
tool in studies on individual host–microbiota interactions using
human biopsy samples (Nigro et al., 2014; Zhao et al., 2015).
THE USE OF INTESTINAL ORGANOIDS
FOR THERAPEUTIC PURPOSES
Intestinal organoids have been transplanted into a damaged colon
for tissue repair (Yui et al., 2012; Fordham et al., 2013; Spurrier
and Grikscheit, 2013; Chen Y. et al., 2015; Elliott et al., 2015;
Joly et al., 2015). Fukuda et al. (2014) described methods for
long-term expansion of Lgr5+ cells in culture. They reintroduced
Lgr5+ cell-derived colon organoids into a superficially damaged
mouse colon, and found that the organoid cells formed a single-
layered functionally and histologically normal epithelium (see
also Barthel et al., 2012; Yui et al., 2012; Gehart and Clevers,
2015). Watson et al. (2014) showed that an in vivo transplant
of ESC- or iPSC-derived human intestinal organoids results
in marked expansion and maturation of the epithelium and
mesenchyme.
In the treatment of IBD, traditional anti-TNF-α therapy based
on the anti-immunologic theory has shown limited long-term
therapeutic responses; accordingly, a stem cell transplantation
therapy involving a 3D-cultured organoid may solve the problem
(Yui et al., 2012; Spurrier and Grikscheit, 2013; Fukuda
et al., 2014; Mokry et al., 2014; Okamoto and Watanabe,
2015). Cultured organoids have been proven to regenerate
damaged epithelial cells in vivo after trans-anal transplantation
(Fordham et al., 2013). Researchers upregulated ILCs in the
GI organoid and then dissociated them into small pieces for
infusion. After the cultured and dissociated organoids are
transplanted into an animal model of dextran sulfate sodium
(DSS)-colitis, they spontaneously move toward the damaged
focus of the DSS-colitis ulcer and promote reconstruction of the
epithelial structure (Fordham et al., 2013). The newly produced
epithelial cells retain their normal functions of the barrier
against infection and of nutrition absorption; these findings
mean that the DSS-caused colitis may be cured (Fordham
et al., 2013). The transplanted cells stay functional for more
than half a year. Consequently, these results indicate that
ISC transplantation may also be adapted to patients with
IBD and elicit a long-term response (Figure 2; Yui et al.,
2012; Fordham et al., 2013). Further studies also revealed that
intestinal organoids can regenerate the colonic mucosa after
inflammation.
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FIGURE 2 | Schematic diagram of mini-gut culture and application to stem cell transplantation. The image shows organoid development from isolated
crypts to round spheres and budding organoids. After the cultured and dissociated organoids are transplanted into animal models or human bodies, they
spontaneously move toward the damaged focus of the DSS-colitis ulcer and promote reconstruction of the epithelial structure.
ENGINEERED CANCER ORGANOIDS
Human colorectal carcinoma (CRC), a common cancer type,
evolves from adenomatous polyps to advanced adenomas,
carcinomas in situ, and adenocarcinomas (Drost et al., 2015).
Mutations in APC, AXIN2, or CTNNB1 are believed to change
a proliferating tissue into invasive and ever-expanding neoplasm
that shows submucosal invasion and causes systemic metastases
(Matano et al., 2015). In the research on human colon cancer,
conventional cancer cell lines and animal models have long
been used for cancer modeling, tumorigenesis studies, and drug
screening. Cell lines cannot form the authentic tissue structure
and acquire mutations after passaging, whereas animal models
take a long time and do not fully reflect genetic characteristics of
human tissues (van de Wetering et al., 2015). Organoids either
from human biopsy samples or from iPSCs may be a solution to
these problems (van de Wetering et al., 2015).
van de Wetering et al. (2015) established a living cancer
biobank of colon organoids derived from either cancer tissue
or adjacent healthy tissue from 20 patients with CRC. Whole-
exome sequencing has been performed on these models along
with tissues from biopsies. They found that the subtypes can
be identified by means of an organoid model of an individual
patient and that in vitro models can fully recapitulate the original
genetic and morphological characteristics (van de Wetering et al.,
2015). In addition, porcupine inhibitor was tested and found to
be effective against an organoid with special alteration of RNF43
(van de Wetering et al., 2015). Furthermore, 35 medications
used for the treatment of CRC have been tested in the biobank,
and their specific targets and possible resistance were thoroughly
analyzed. This effort may point to an effective strategy for a
precision therapy via drug screening and gene analysis and
correction (van de Wetering et al., 2015).
Additionally, genetic engineering by means of the
CRISPR/Cas9 system has been applied to the remodeling of
colorectal cancer (Onuma et al., 2013; Li et al., 2014; Drost
et al., 2015; Matano et al., 2015; Salahudeen and Kuo, 2015).
When APC, TP53, KRAS, and SMAD4 genes are knocked out
in a cultured human colon organoid, the engineered organoid
can grow independently from niche factors and shows tumor
morphology and invasive features after a transplant into an
animal (Drost et al., 2015). Moreover, after these driver genes
are altered in an adenoma organoid originating from patients,
the latter dramatically propagates and yields distant metastases
(McCracken et al., 2014). According to the results of Drost et al.
(2015), chromosomal instability and aneuploidy can be caused
and mainly mediated by APC and TP53, which are important for
malignant transformation into CRC. In addition, when an APC
mutation is corrected in a colon adenoma or adenocarcinoma,
the epithelial differentiation is rescued and preserved, and the
homeostasis is then restored (Dow et al., 2015).
Nevertheless, the cancer that is engineered in an organoid
possesses aberrations only in driver genes, not in DNA
methylation, and mainly progresses along the adenoma route
(Dow et al., 2015). When transplanted into a renal subcapsular
region in animals, the engineered organoid does not expand
or metastasize effectively as compared with the original-CRC-
derived organoid (Salahudeen and Kuo, 2015). In agreement
with the findings of Drost et al. (2015), an organoid line with a
quadruple knockout of APC, TP53, KRAS, and SMAD4 shows
only limited capacity for invasion into the cancer stroma. To
solve these problems, additional modifications such as epigenetic
changes and chromosomal instability should be introduced into
the existing engineered models. Possibly, a newly designed
model containing all these oncogenic factors and mutations will
acquire both histological features and powerful proliferative and
metastatic abilities.
DRUG SCREENING
Newly developed medical treatments of human diseases usually
have limitations such as individual differences among patients,
difficulty with prediction of outcomes, and time-consuming drug
testing (Eglen and Randle, 2015; Martin, 2015; Sampaziotis et al.,
2015; Dedhia et al., 2016). Precision medicine is now coming into
focus and becoming more relevant to clinical practice (Mou et al.,
2015; VanDussen et al., 2015). 3D organoid culture based on a
specific disease and even on a specific individual is expected to
develop into a powerful tool of precision therapy (Hynds and
Giangreco, 2013; Eglen and Randle, 2015; Walsh et al., 2016).
Primary cancers, infectious diseases, and developmental diseases
can be replicated ex vivo on biopsy samples from patients, as is the
case for the biobank of colon cancer organoids (van de Wetering
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et al., 2015). These kinds of “live” clinical specimens may become
useful for drug testing, gene editing, or for research on prognosis.
Prostate cancer organoids, generated from castration-resistant
Nkx3.1-expressing cells, have also been tested in modeling of a
drug response (Chua et al., 2014). A tumor organoid originating
from a mouse or human tissue or after oncogenic transformation
can maintain genetic and phenotypic characteristics of its
progenitor; accordingly, the Akt inhibitor MK-2206 and the
mechanistic target of rapamycin (mTOR) inhibitor ridaforolimus
have been proven to be significantly effective against organoid
formation; these findings are consistent with the already-known
AR and PI(3)K signaling activation in prostate cancer (Chua
et al., 2014). Another group studied advanced prostate cancer
models based on castration-resistant prostate cancer and found
that a patient-derived organoid can recapitulate the in vitro
results, and genetic manipulations hold promise (Gao et al.,
2014). All these results suggest that an ex vivo prostate organoid
can– potentially be used for drug research.
Organoids from primary human pancreatic ductal
adenocarcinoma (PDAC) have been used to identify new
effective drugs (Huang et al., 2015; Nielsen et al., 2016). Patient-
derived tumor organoids show similar histoarchitecture features
and differentiation markers expression level with primary
tumor (Huang et al., 2015). Even histological features like
different populations of invasive glands could be conserved
in tumor organoids (Huang et al., 2015). Five human tumors
with a poor response to chemotherapy were selected, and the
organoid models that were derived from them were tested with
epigenetically targeted drugs. As a result, some of the organoids
showed decreased proliferation after treatment, thus indicating
new therapeutic targets in this cancer. Because PDAC patients
harbor numerous genetic and epigenetic changes, organoid
models may be a good solution for fast drug selection and
validation.
As for other solid tumors such as glioblastoma, primary cancer
cell lines can be isolated from patients, and then they could be
made into patient-derived xenograft models or directly cultured
in a 3D matrix (Eglen and Randle, 2015). Unlike slices of tumor
samples, the tumor cell lines may provide more dynamic and
detailed clinical information and could be applied to analysis
of cancer-associated signaling pathways (Shamir and Ewald,
2014). When digested and cultured in a 3D matrix, a tumor
organoid from different sources shows varied morphological
features and indolent or high invasion, in accordance with
a clinical prognostic outcome. After treatment with radiation,
different glioblastoma lines showed varied chemotherapeutic
drug responses, with implications for clinical practice (Shamir
and Ewald, 2014).
For other 3D tumor organoids such as breast cancer
organoid and lung cancer organoid, although no clinical
trials are underway before now, drug screening platforms
through organoid proved to be a useful preclinical model for
pharmacodynamic profiling of human tumors (Vaira et al., 2010;
Rookmaaker et al., 2015; Walsh et al., 2016). All these approaches
to analysis of (and intervention into) diseases by means of an
organoid system should expand the basic knowledge about the
relevant diseases and improve the management of patients.
A SUMMARY AND FUTURE DIRECTIONS
In vitro organoid models, with the capacity for rapid growth,
stable differentiation, and suitability for non-mutational and
genetic manipulations, have become an effective tool for human
disease research and a powerful weapon of precision therapy (de
Lau et al., 2012; Spurrier and Grikscheit, 2013; Forster et al.,
2014; Todhunter et al., 2015). The culture system can consist of
a mixture of already existing internal cells such as endothelial
cells, Paneth cells, or peripheral T cells, or alternatively, growth
factors secreted by internal functioning cells in a complete
culture medium. Eventually, the organoid is expected to acquire
characteristics similar to those of a healthy or diseased organ
(Moore et al., 2014; Sugimoto et al., 2015; Overeem et al., 2016).
The CRISPR/Cas9 system also enables researchers to implement
gene modifications in vitro, which are hard to accomplish directly
in a human body (Guye et al., 2016). Therefore, wild-type or
disease-causing genes along with their downstream effects can be
analyzed in a more rapid and reliable manner, and the off-target
effects manifest themselves less after correction of genes in an
organoid (Lutsenko, 2016). Genetically modified organoids have
been successfully transplanted into a damaged colon for tissue
repair and function recovery. Besides, research on engineered
cancer together with clinical genome databases can be harnessed
to deliver disease-causing genes into a mini-organ and induce
it to proliferate into invasive and metastatic cancer organoid
lines that even cause similar systemic metastasis after they are
returned into the human body (Kazanjian and Shroyer, 2011;
Cancer Genome Atlas Network, 2012; Cooks et al., 2013). A large
database of human individualized diseases has been created and
studied via generation of tissue organoids based on biopsies. All
these methods contribute to research on tumorigenesis and drug
screening (de Lau et al., 2012; Basak et al., 2014; DeWard et al.,
2014).
Surely, the organoid system has its limitations. First, the
limited number of cell types in intestinal epithelial organoids
and the absence of the immune, nervous, and vascular system
in cultured intestinal organoids result in drug effects that are
different from those in vivo (Fuller et al., 2012; Jabaji et al.,
2013; Grun et al., 2015). Additionally, although the main cell
types of epithelial cells that are generated in organoids are
similarly diverse in comparison with those found in vivo, the
3D organization cannot be spatially and structurally similar
to an in vivo murine intestine or consistent with other
organoids (Onuma et al., 2013; Wieck et al., 2015). Third, the
microenvironment and hormone levels, pH, and the health status
of the human body as well as epigenetic factors cannot be fully
reproduced in an ex vivo organoid (Lancaster and Knoblich, 2014;
Dekkers et al., 2015; Wroblewski et al., 2015). In addition, a wider
range of disease databases needs to be established and extensively
tested (Stedman et al., 2015; Xinaris et al., 2015; Fatehullah et al.,
2016).
To solve these problems, a new disease profile of an organoid
model and an effective co-culture system that mimics the in vivo
intestinal system are necessary (Lancaster and Knoblich, 2014;
Chen E.C. et al., 2015; Rookmaaker et al., 2015; Salahudeen and
Kuo, 2015; Tamminen et al., 2015). Recently, a variety of intestinal
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culture systems combined with nerve or mesenchymal cells
have been established (Takebe et al., 2015; Pastula et al., 2016).
Furthermore, additional functional models involving an organoid
and a pathogen should be devised to identify various pathways
leading to human infectious diseases (Yin et al., 2016). Especially
for chronic inflammation, new models are necessary to obtain
more direct and convincing evidence for more detailed research
into the role of chronic inflammation in carcinogenesis (Watson
et al., 2014; Wiener et al., 2014; Sinagoga and Wells, 2015).
Infectious organoids can also be genetically manipulated to study
genes and epigenetic factors in the development of inflammation
(Fujii et al., 2015; Lutsenko, 2016). The CRISPR/Cas9-mediated
correction has been successfully applied to the CFTR mutation
for the treatment of patients with CF (Durand et al., 2012; Liu
et al., 2012; Schwank et al., 2013; Martin, 2015; Mou et al., 2015;
Dedhia et al., 2016). Identification and correction of candidate
genes for targeted therapy may open up new opportunities for
treatment of immune diseases. Biobanks of either oncological
or inflammatory diseases pave the way for new drugs to clinical
practice (Eglen and Randle, 2015; Martin, 2015; Mou et al., 2015;
Walsh et al., 2016).
Researchers also need to analyze signaling pathways leading
to NF-κB activation in systems that inhibit bacterial proliferation
(Wroblewski et al., 2015; Guye et al., 2016). Regarding the ISC
transplantation therapy, further studies are needed to identify
a possible pathogen and to clarify the effects on organoids
and on the intestinal mucosa (Forster et al., 2014; Todhunter
et al., 2015; Xinaris et al., 2015). After a transplant into
mice, intestinal organoids can acquire villus-like structures that
may be modified for future clinical applications. For precision
therapy and drug screening, the organoid models for testing
need to be created and standardized more quickly to better
uncover gene–drug associations and to obtain more accurate
prognostic information. The new choice of a 3D culturing matrix
and detailed protein composition may reflect natural organ
microenvironments better. Finally, as data on organoid responses
during drug screening and data on genetic profiles are generated,
it is necessary to analyze their positive correlations for timely
clinical decisions and for prediction of responses to treatment.
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